Payment overview · 2025
General Payments
$3,586.18
190 reported records · 37 companies
Healthcare provider profile · identity verified
Walter James Evans, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FLORENCE, SC · NPI 1871609388
Verified facts
What the public records show
CMS Open Payments records show Walter James Evans, MD received $3,586.18 in general payments during 2025 across 190 reported records.
UCB, Inc. accounted for 10.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 46 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Austedo Xr, Briviact, Epidiolex, Fycompa, Gamunex-C, Gocovri, Ingrezza, Nurtec Odt, Qulipta, Tysabri, Ubrelvy, Valtoco, Vumerity.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Ubrelvy by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rytary by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PLEGRIDY as an associated drug or biological on 39 records involving 31 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Plegridy by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TECFIDERA as an associated drug or biological on 28 records involving 22 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Tecfidera by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TYSABRI as an associated drug or biological on 12612 records involving 3572 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Tysabri by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VUMERITY as an associated drug or biological on 16193 records involving 4044 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Vumerity by this doctor in 2024.
CATALYST PHARMACEUTICALS, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FYCOMPA as an associated drug or biological on 3130 records involving 1101 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Fycompa by this doctor in 2024.
Grifols USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gamunex-C as an associated drug or biological on 3977 records involving 2134 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Gamunex-C by this doctor in 2024.
JAZZ PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EPIDIOLEX as an associated drug or biological on 10990 records involving 3626 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Epidiolex by this doctor in 2024.
MDD US Operations, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gocovri as an associated drug or biological on 3202 records involving 1029 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Gocovri by this doctor in 2024.
Neurelis, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VALTOCO as an associated drug or biological on 16082 records involving 5567 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Valtoco by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Ingrezza by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Nurtec Odt by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Xcopri by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAGARD LIQUID as an associated drug or biological on 29 records involving 8 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Gammagard Liquid by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Austedo by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Austedo Xr by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 248 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| UCB, Inc. | Unresolved — no canonical attribution shown | $374.82 | 10.4% | 17 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $302.81 | 8.4% | 29 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $216.77 | 6.0% | 14 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $199.62 | 5.6% | 13 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $196.79 | 5.5% | 10 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $188.32 | 5.2% | 9 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $171.38 | 4.8% | 7 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $157.80 | 4.4% | 7 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $129.52 | 3.6% | 4 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$123.17 | 3.4% | 6 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $122.27 | 3.4% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $101.38 | 2.8% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $96.19 | 2.7% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $95.03 | 2.6% | 5 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $83.36 | 2.3% | 4 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $80.48 | 2.2% | 4 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $71.37 | 2.0% | 4 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $69.53 | 1.9% | 3 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $66.38 | 1.9% | 3 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $63.85 | 1.8% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $63.17 | 1.8% | 3 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $62.40 | 1.7% | 3 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $56.46 | 1.6% | 3 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$54.95 | 1.5% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $53.30 | 1.5% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $53.11 | 1.5% | 3 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $48.36 | 1.4% | 2 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $46.38 | 1.3% | 2 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $41.57 | 1.2% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $39.91 | 1.1% | 2 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $30.59 | 0.8% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $26.94 | 0.8% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $25.01 | 0.7% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $24.06 | 0.7% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.40 | 0.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.40 | 0.4% | 1 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $15.33 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,586.18 | 190 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $274.32 | 25 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $196.79 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $192.20 | 11 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $171.38 | 7 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $148.22 | 7 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $130.86 | 6 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $129.52 | 4 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $122.27 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $119.37 | 6 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $103.27 | 5 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $103.27 | 5 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $102.17 | 6 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $102.17 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $97.78 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $97.45 | 7 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $97.45 | 7 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $95.03 | 5 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $90.44 | 4 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $86.33 | 3 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $83.36 | 4 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $80.48 | 4 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $78.20 | 4 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $67.19 | 4 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $64.53 | 3 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $63.85 | 3 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $62.40 | 3 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $56.46 | 3 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $54.95 | 3 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $53.11 | 3 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $48.36 | 2 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $46.38 | 2 | 2025 |
Source payment records
|
|||||
| ELYXYB - CELECOXIB Normalized: elyxyb celecoxib |
Drug | SCILEX PHARMACEUTICALS INC. | $46.26 | 2 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $41.57 | 2 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $39.91 | 2 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $36.48 | 2 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $36.34 | 2 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $35.03 | 2 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $30.59 | 2 | 2025 |
Source payment records
|
|||||
| Xembify Normalized: xembify |
Biological | Grifols USA, LLC | $29.90 | 1 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $28.49 | 4 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $26.94 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $23.27 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $15.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AUSTEDO XR austedo xr |
2025 | Austedo Xr | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Briviact briviact |
2025 | Briviact | 2024 | 248 | exact normalized | Medicare Part D |
| EPIDIOLEX epidiolex |
2025 | Epidiolex | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FYCOMPA fycompa |
2025 | Fycompa | 2024 | 75 | exact normalized | Medicare Part D |
| Gamunex-C gamunex c |
2025 | Gamunex-C | 2024 | 77 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Gocovri gocovri |
2025 | Gocovri | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 52 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TYSABRI tysabri |
2025 | Tysabri | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VALTOCO valtoco |
2025 | Valtoco | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VUMERITY vumerity |
2025 | Vumerity | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | PLEGRIDY open payments reported associated product |
CMS Open Payments — General Payments 39 supporting records · 31 recipient NPIs · example record 1208305761 |
Plegridy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | TECFIDERA open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 22 recipient NPIs · example record 1208304358 |
Tecfidera · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | TYSABRI open payments reported associated product |
CMS Open Payments — General Payments 12612 supporting records · 3572 recipient NPIs · example record 1208299693 |
Tysabri · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | VUMERITY open payments reported associated product |
CMS Open Payments — General Payments 16193 supporting records · 4044 recipient NPIs · example record 1208299697 |
Vumerity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| CATALYST PHARMACEUTICALS, INC. Exact reporting entity; no affiliate inference |
2025 | FYCOMPA open payments reported associated product |
CMS Open Payments — General Payments 3130 supporting records · 1101 recipient NPIs · example record 1253216846 |
Fycompa · 2024 Exact normalized brand match · 1 Part D row |
75 | 12 |
| Grifols USA, LLC Exact reporting entity; no affiliate inference |
2025 | Gamunex-C open payments reported associated product |
CMS Open Payments — General Payments 3977 supporting records · 2134 recipient NPIs · example record 1249529381 |
Gamunex-C · 2024 Exact normalized brand match · 1 Part D row |
77 | suppressed by CMS |
| JAZZ PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | EPIDIOLEX open payments reported associated product |
CMS Open Payments — General Payments 10990 supporting records · 3626 recipient NPIs · example record 1234297758 |
Epidiolex · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| MDD US Operations, LLC Exact reporting entity; no affiliate inference |
2025 | Gocovri open payments reported associated product |
CMS Open Payments — General Payments 3202 supporting records · 1029 recipient NPIs · example record 1241843637 |
Gocovri · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Neurelis, Inc. Exact reporting entity; no affiliate inference |
2025 | VALTOCO open payments reported associated product |
CMS Open Payments — General Payments 16082 supporting records · 5567 recipient NPIs · example record 1219183925 |
Valtoco · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
52 | 13 |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GAMMAGARD LIQUID open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 8 recipient NPIs · example record 1223786557 |
Gammagard Liquid · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
248 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 372 | 71 |
| Donepezil Hcl | Donepezil Hcl | 308 | 74 |
| Topiramate | Topiramate | 305 | 74 |
| Briviact | Brivaracetam | 248 | 22 |
| Oxcarbazepine | Oxcarbazepine | 247 | 48 |
| Memantine Hcl | Memantine Hcl | 197 | 45 |
| Clonazepam | Clonazepam | 195 | 32 |
| Pregabalin | Pregabalin | 191 | 38 |
| Levetiracetam | Levetiracetam | 186 | 36 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 180 | 37 |
| Alprazolam | Alprazolam | 170 | 21 |
| Phenobarbital | Phenobarbital | 149 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 146 | 33 |
| Lacosamide | Lacosamide | 134 | 16 |
| Baclofen | Baclofen | 130 | 29 |
| Mirtazapine | Mirtazapine | 125 | 26 |
| Divalproex Sodium Er | Divalproex Sodium | 113 | 17 |
| Divalproex Sodium | Divalproex Sodium | 109 | 14 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 105 | 20 |
| Aimovig Autoinjector | Erenumab-Aooe | 100 | 15 |
| Lamotrigine | Lamotrigine | 89 | suppressed |
| Rufinamide | Rufinamide | 80 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 77 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 76 | 14 |
| Fycompa | Perampanel | 75 | 12 |
| Carbamazepine Er | Carbamazepine | 74 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 74 | 24 |
| Famciclovir | Famciclovir | 71 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 71 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 19 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 68 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 67 | suppressed |
| Kesimpta Pen | Ofatumumab | 66 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | 14 |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 64 | 13 |
| Diazepam | Diazepam | 62 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 62 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 60 | 13 |
| Carisoprodol | Carisoprodol | 59 | suppressed |
| Lamotrigine Er | Lamotrigine | 55 | suppressed |
| Entacapone | Entacapone | 53 | suppressed |
| Dalfampridine Er | Dalfampridine | 52 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 52 | 13 |
| Xcopri | Cenobamate | 47 | suppressed |
| Prednisone | Prednisone | 45 | 21 |
| Gammaked | Immune Globul G/Gly/Iga Avg 46 | 43 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 42 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 42 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 41 | suppressed |
| Temazepam | Temazepam | 40 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 39 | suppressed |
| Lorazepam | Lorazepam | 39 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 38 | suppressed |
| Ubrelvy | Ubrogepant | 38 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 35 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 35 | suppressed |
| Nourianz | Istradefylline | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Clobazam | Clobazam | 33 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Austedo Xr | Deutetrabenazine | 30 | suppressed |
| Ingrezza | Valbenazine Tosylate | 30 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 28 | suppressed |
| Primidone | Primidone | 27 | 13 |
| Promethazine Hcl | Promethazine Hcl | 27 | suppressed |
| Qulipta | Atogepant | 27 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 26 | suppressed |
| Austedo | Deutetrabenazine | 25 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 25 | suppressed |
| Amantadine | Amantadine Hcl | 24 | suppressed |
| Epidiolex | Cannabidiol (Cbd) | 23 | suppressed |
| Phenytoin | Phenytoin | 23 | suppressed |
| Vumerity | Diroximel Fumarate | 23 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 22 | suppressed |
| Risperidone | Risperidone | 22 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Misoprostol | Misoprostol | 18 | suppressed |
| Neupro | Rotigotine | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Rytary | Carbidopa/Levodopa | 18 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Gocovri | Amantadine Hcl | 17 | suppressed |
| Levetiracetam Er | Levetiracetam | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Aubagio | Teriflunomide | 15 | suppressed |
| Horizant | Gabapentin Enacarbil | 14 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 14 | suppressed |
| Valtoco | Diazepam | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Oxtellar Xr | Oxcarbazepine | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Tysabri | Natalizumab | 13 | suppressed |
| Armodafinil | Armodafinil | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Lamotrigine Odt | Lamotrigine | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Octagam | Immun Globg(Igg)/Malt/Iga Ov50 | 12 | suppressed |
| Onfi | Clobazam | 12 | suppressed |
| Plegridy | Peginterferon Beta-1a | 12 | suppressed |
| Tecfidera | Dimethyl Fumarate | 12 | suppressed |
| Tiagabine Hcl | Tiagabine Hcl | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 11 | suppressed |
| Avonex Pen (4 Pack) | Interferon Beta-1a | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,586.18 · 190 records | UCB, Inc. | ACTHAR, AJOVY, AMVUTTRA, AUSTEDO XR, BRIUMVI, Briviact, CREXONT, ELYXYB - CELECOXIB, EPIDIOLEX, FYCOMPA, Fintepla, Gamunex-C, Gocovri, HYQVIA, INGREZZA, KESIMPTA, LEQEMBI, NUPLAZID, NURTEC ODT, Nayzilam, OCTAGAM IMMUNE GLOBULIN (HUMAN), ONPATTRO, Ocrevus Zunovo, PANZYGA, PONVORY, QULIPTA, Qelbree, REXULTI, Rystiggo, Sunosi, TYSABRI, UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VUMERITY, VYEPTI, VYVGART, VYVGART HYTRULO, WAINUA, WAKIX, Xembify, ZAVZPRET, ZEPBOUND, ZEPOSIA, ZTLido | 19 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Austedo Xr play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error